Standout Papers

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis fact... 2009 2026 2014 2020 418
  1. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial (2009)
    Josef S Smolen, Jonathan Kay et al. The Lancet

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 82 standout
Sub-graph 1 of 19

Citing Papers

Therapeutic advances in rheumatoid arthritis
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
10 intermediate papers

Works of Yiying Zhou being referenced

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
2012
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2009 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Yiying Zhou 1047 212 188 570 569 61 1.6k
Elizabeth M. Kudlacz 609 53 160 686 418 55 1.8k
I Portioli 655 79 205 307 220 72 1.6k
H Häntzschel 551 79 73 442 101 57 1.3k
Udayasankar Arulmani 466 72 68 268 210 36 1.4k
Tania Colasanti 630 157 34 506 167 66 1.8k
Berta Martins da Silva 212 117 105 364 173 56 1.3k
John C. Lockhart 345 45 364 214 710 53 1.7k
Yu‐Wen Su 269 175 149 516 98 71 2.0k
Gilles Edan 310 60 122 203 255 66 1.8k
Stevan Shaw 341 42 26 721 200 41 1.4k

All Works

Loading papers...

Rankless by CCL
2026